Formulation for the parenteral application of a sodium channel blocker
AssigneeBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
InventorsBernd Kruss, Annerose Mauz, Karin Ruehr, Jean-Marie Stassen, Claus Veit, Klaus Wagner
Life of this patent
Estimating the term…
Abstract
The invention relates to a new formulation containing BIII 890 or one of the pharmaceutically acceptable salts thereof for parenteral administration.
Claims30
Pharmaceutical composition comprised of a cyclodextrin complex of BIII 890 or a pharmacologically acceptable salt thereof.
Pharmaceutical composition comprised of a ternary complex consisting of BIII 890 or a pharmacologically acceptable salt thereof, a cyclodextrin and a hydroxy acid.
Pharmaceutical composition comprised of BIII 890 or one of the pharmacologically acceptable salts thereof in combination with a substituted or unsubstituted cyclodextrin.
A complex of BIII 890 or one of the pharmacologically acceptable salts thereof with a cyclodextrin as complexing agent.
A method of treating stroke in a patient needing such treatment by administering a therapeutically effective amount of a pharmaceutical composition comprised of BIII 890 or one of the pharmacologically acceptable salts thereof and
- a) a cyclodextrin complex or
- b) a cyclodextrin complex in the presence of a hydroxy acid.
Method of treating stroke by administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprised of BIII 890 or one of the pharmacologically acceptable salts thereof and cyclodextrin.
Process for preparing a pharmaceutical composition for parenteral administration for the treatment of stroke containing BIII 890 or one of the pharmacologically acceptable salts thereof, characterised in that the active substance is present in the form of
- a) a cyclodextrin complex or
- b) a cyclodextrin complex in the presence of a hydroxy acid.
Dependencies are inferred from the claim text.